Illumina launches genomics incubator in China

By The Science Advisory Board staff writers

February 2, 2021 -- Illumina has partnered with investment firm Sequoia Capital China to launch a new collaboration designed to create an incubator for startup companies in the life sciences that have a focus on genomics.

The Sequoia Capital China Intelligent Healthcare Genomics Incubator is intended to create a startup ecosystem in China to help firms develop breakthrough applications in genomics. The companies hope to replicate the success that the Illumina Accelerator project has had in fostering venture-backed startup firms in the U.S. and U.K.

The incubator will have two six-month funding cycles per year and will give startup firms access to investment and business guidance from Sequoia Capital China. They will also gain access to Illumina sequencing systems and reagents, as well as the company's genomics expertise, and its fully operational lab space in Shanghai.

The incubator's first funding cycle will begin in fall 2021.

Copyright © 2021
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here